FDA Oncology Announcements

Anti-RANKL × Clear all

3 Announcements

FDA Approves Denosumab

Drug: Xgeva (denosumab) · Anti-RANKL antibody
Condition: Sarcoma

Denosumab (Prolia)

Drug: Prolia (denosumab) · Anti-RANKL antibody
Conditions: BreastGenitourinary

Denosumab

Drug: Xgeva (denosumab) · Anti-RANKL antibody
Condition: Plasma cell